文献速递妇科

帕博利珠单抗治疗复发性Lynch样与散发性微卫星不稳定子宫内膜癌的2期试验(NCT02899793):更新生存与缓解分析

A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses.
PubMed 文献 · Gynecol Oncol · 2025-05-06

这项前瞻性2期研究纳入经全外显子测序等确认的复发性铂耐药MSI-H/dMMR子宫内膜癌患者,接受帕博利珠单抗200 mg每3周一次最多24个月。近97人年随访后,Lynch样亚组(n=6)客观缓解率100%高于甲基化亚组(n=18)的44%(Fisher精确检验P=0.024),无进展生存和总生存也优于甲基化亚组。

要点

  • Lynch样亚组客观缓解率100%,甲基化亚组44%(Fisher精确检验P=0.024)。
  • Lynch样亚组无进展生存未达到,甲基化亚组14.6个月(Log-Rank检验P=0.005)。
  • Lynch样亚组总生存未达到,甲基化亚组32.6个月(Log-Rank检验P=0.058)。

核心结论

  • 成熟随访结果继续提示,在接受帕博利珠单抗治疗的MSI-H/dMMR子宫内膜癌患者中,Lynch样与甲基化特征在客观缓解率、无进展生存和总生存方面具有预后意义。
  • 作者认为未来针对MSI-H/dMMR子宫内膜癌患者的免疫检查点抑制剂临床试验中,可能有必要按这些转化特征进行分层。

研究设计与样本

  • 前瞻性2期研究(NCT02899793),纳入经免疫组化、聚合酶链反应和MLH-1甲基化检测确认的可测量MSI-H/dMMR复发性铂耐药子宫内膜癌患者。
  • 肿瘤经全外显子测序和FoundationOne平台测序,以识别Lynch、Lynch样和MLH-1甲基化特征,随后接受帕博利珠单抗200 mg每3周一次、最多24个月。
  • 主要终点为客观缓解率,次要终点为无进展生存和总生存。

主要发现

  • 近97人年随访后,Lynch样亚组(n=6)客观缓解率为100%,甲基化亚组(n=18)为44%(Fisher精确检验P=0.024)。
  • Lynch样亚组无进展生存未达到,甲基化亚组为14.6个月(Log-Rank检验P=0.005)。
  • Lynch样亚组总生存未达到,甲基化亚组为32.6个月(Log-Rank检验P=0.058)。
  • 两组MSI-H患者的毒性均可管理。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为未来免疫检查点抑制剂临床试验中可能有必要按Lynch样与甲基化等转化特征进行分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) is a biomarker for response to immune checkpoint inhibitors. We report updated results including objective response rate, progression free survival, and overall survival data with 5-year follow-up in recurrent platinum-resistant, MSI-H, endometrial cancer (EC) patients fully sequenced using whole exome sequencing (WES) and treated within a prospective phase II study with pembrolizumab (NCT02899793). METHODS: Tumors from patients with measurable MSI-H/dMMR endometrial cancer confirmed by immunohistochemistry, polymerase chain reaction, and MLH-1 methylation assays were sequenced using whole exome sequencing and the FoundationOne platform for the identification of Lynch, Lynch-like, and MLH-1 methylated characteristics before receiving pembrolizumab 200 mg every 3 weeks for up to 24 months. The primary endpoint was objective response rate (ORR), and secondary endpoints were progression free survival (PFS), and overall survival (OS). RESULTS: After almost 97 person-years of follow-up, the Lynch-like subgroup (n = 6) of MSI-H/dMMR patients continues to exhibit better ORR than the methylated (n = 18) subgroup (100 % versus 44 %, Fisher's exact P = 0.024), as well as improved PFS (unreached for Lynch-like versus 14.6 months, Log-Rank P = 0.005) and improved OS (unreached for Lynch-like versus 32.6 months, Log-Rank P = 0.058). Toxicity was manageable in both groups of MSI-H patients. CONCLUSION: Mature follow-up results continue to suggest the prognostic significance of Lynch-like versus methylated MSI-H/dMMR features in endometrial cancer patients treated with pembrolizumab in terms of ORR, PFS, and OS. Stratification for these translational aspects may be warranted in future clinical trials with immune checkpoint inhibitors in MSI-H/dMMR endometrial cancer patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ettorre VM, Bellone S, Greenman M, et al. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecol Oncol. 2025. PMID: 40334308. doi:10.1016/j.ygyno.2025.04.591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。